German Tamoxifen Shortage Shows Consequences Of Cost Containment
Medicines For Europe Urges Change To ‘Unsustainable’ Procurement Policies
Supply issues around breast cancer treatment tamoxifen in Germany demonstrate the damaging effects of European cost-containment measures, Medicines for Europe has warned, citing an “urgent need to revise unsustainable pricing and tendering policies.”
You may also be interested in...
Pfizer’s biosimilars commercial lead, Roman Irsiegler, has set out his views on policy obstacles for biosimilars that need to be addressed if the market is to sustainably deliver on its potential.
Markus Sieger, vice-president of off-patent industry association Medicines for Europe and CEO of Polpharma, spoke to Generics Bulletin about critical issues affecting supply in Europe, including pricing, supply chains, and his enthusiasm for ESG.
A fresh report has offered stark new data on the extent to which generics are disappearing from the European market. Industry association Medicines for Europe has pointed to the risks of supply consolidation, urging both national- and EU-level action.